NEW YORK (GenomeWeb News) – Diagnoplex and Unilabs said today that they have signed an agreement to commercialize Colox, Diagnoplex's minimally invasive colorectal cancer assay, within the Unilabs network.

The test will be available initially in the Swiss and Swedish markets, the companies said.

Colox, Diagnoplex's lead product, is a PCR-based test intended for the systematic screening of colorectal cancer. The gene signature underlying Colox has been designed to detect early and advanced disease stages with "outstanding results and reliability," said Diagnoplex.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.